RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.15.22272426
DO 10.1101/2022.03.15.22272426
A1 Montez-Rath, Maria E.
A1 Garcia, Pablo
A1 Han, Jialin
A1 Cadden, LinaCel
A1 Hunsader, Patti
A1 Morgan, Curt
A1 Kerschmann, Russell
A1 Beyer, Paul
A1 Dittrich, Mary
A1 Block, Geoffrey A
A1 Anand, Shuchi
A1 Parsonnet, Julie
A1 Chertow, Glenn M
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.15.22272426.abstract
AB Background It is unclear whether a third dose of mRNA platform vaccines, or antibody response to prior infection or vaccination confer protection from the Omicron variant among patients receiving dialysis.Methods Monthly since February 2021, we tested plasma from 4,697 patients receiving dialysis for antibodies to the receptor-binding domain (RBD) of SARS-CoV-2. We assessed semiquantitative median IgG index values over time among patients vaccinated with at least one dose of the two mRNA vaccines. We ascertained documented COVID-19 diagnoses after December 25, 2021 and up to January 31, 2022. We estimated the relative risk for documented SARS-CoV-2 infection by vaccination status using a log-binomial model accounting for age, sex, and prior clinical COVID-19. Among patients with RBD IgG index value available during December 1-December 24, 2021, we also evaluated the association between the circulating RBD IgG titer and risk for Omicron variant SARS-CoV-2 infection.Results Of the 4,697 patients we followed with monthly RBD assays, 3576 are included in the main analysis cohort; among these, 852 (24%) were unvaccinated. Antibody response to third doses was robust (median peak index IgG value at assay limit of 150, equivalent to 3270 binding antibody units/mL). Between December 25-January 31, 2022, SARS-CoV-2 infection was documented 340 patients (7%), 115 (36%) of whom were hospitalized. The final doses of vaccines were given a median of 272 (25th, 75th percentile, 245-303) days and 58 (25th, 75th percentile, 51-95) days prior to infection for the 1-2 dose and 3 dose vaccine groups respectively. Relative risks for infection were higher among patients without vaccination (RR 2.1 [95%CI 1.6, 2.8]), and patients with 1-2 doses (RR 1.3 [95%CI 1.0, 1.8]), compared with patients with three doses of the mRNA vaccines. Relative risks for infection were higher among patients with RBD index values < 23 (506 BAU/mL), compared with RBD index value ≥ 23 (RR 2.4 [95%CI 1.9, 3.0]). The higher risk for infection among patients with RBD index values < 23 was present among patients who received three doses (RR 2.1 [95%CI 1.3, 3.4]).Conclusions Among patients receiving hemodialysis, patients unvaccinated, without a third mRNA vaccine dose, or those lacking robust circulating antibody response are at higher risk for Omicron variant infection. Low circulating antibodies could identify the subgroup needing intensified surveillance, prophylaxis or treatment in this patient population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAscend Clinical Laboratory supported the remainder plasma testing for SARS-CoV-2 antibodies. Dr. Anand was supported by grant R01DK127138 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Garcia is supported by the Leeds Compassionate Scholar Fund (Stanford University). Dr. Chertow was supported by grant K24DK085446 from the National Institute of Diabetes and Digestive and Kidney Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethics approval from Stanford University. Stanford University investigators received anonymized data, and the Institutional Review Board waived the requirement for consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData set: Available upon investigators' review of request, with age categories further collapsed to ensure anonymization. The analytical data set may be subject to a data sharing agreement with U.S. Renal Care.